NLS Pharmaceutics AG Total Liabilities
NLS Pharmaceutics AG total liabilities. Based on the latest financial reports, NLS Pharmaceutics AG (NLSP) has total liabilities worth $1.46 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of NLS Pharmaceutics AG to measure how many days the company can operate on defensive assets alone.
Total Liabilities of NLS Pharmaceutics AG (2017–2024)
Total liabilities of NLS Pharmaceutics AG from 2017 to 2024. This chart illustrates how NLS Pharmaceutics AG's total liabilities have evolved over time, based on quarterly financial data.
NLS Pharmaceutics AG Competitors by Total Liabilities
The table below lists competitors of NLS Pharmaceutics AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Blue Coast Hotels Limited
NSE:BLUECOAST
|
India | Rs285.76 Million |
|
PLENUM AG NA O.N.
F:PLEK
|
Germany | €8.32 Million |
|
YouGov plc
LSE:YOU
|
UK | GBX377.90 Million |
|
Tourn International AB
ST:TOURN
|
Sweden | Skr20.46 Million |
|
Wi2Wi Corporation
V:YTY
|
Canada | CA$5.74 Million |
|
BACTECH ENVIRONMENT.CORP.
F:0BT1
|
Germany | €4.90 Million |
|
Frp Advisory Group Plc
LSE:FRP
|
UK | GBX63.10 Million |
|
Madoro Metals Corp
V:MDM
|
Canada | CA$62.26K |
Liability Composition Analysis (2017–2024)
This chart breaks down NLS Pharmaceutics AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NLSP asset base.
Liquidity & Leverage Metrics
NLS Pharmaceutics AG Total Liabilities Ratios Explained
NLS Pharmaceutics AG total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NLS Pharmaceutics AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NLS Pharmaceutics AG (2017–2024)
The table below shows the annual total liabilities of NLS Pharmaceutics AG from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $826.76K | -92.26% |
| 2023-12-31 | $10.68 Million | +78.13% |
| 2022-12-31 | $6.00 Million | +14.81% |
| 2021-12-31 | $5.22 Million | -48.78% |
| 2020-12-31 | $10.20 Million | +48.46% |
| 2019-12-31 | $6.87 Million | -23.35% |
| 2018-12-31 | $8.96 Million | -10.46% |
| 2017-12-31 | $10.01 Million | -- |
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity … Read more